Bruker and the University of Victoria-Genome British Columbia Proteomics Centre have announced a collaborative effort for the development and validation of high-throughput assays for determining hemoglobin variants and diabetes risk, using Bruker´s MALDI Biotyper platform for clinical mass spectrometry, and based on intellectual property developed at the UVic GBC Proteomics Centre.
You can read the full press release
here.
